Literature DB >> 28717940

Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.

Ralph M Trüeb1, Maria Fernanda Reis Gavazzoni Dias2.   

Abstract

Alopecia areata is a common hair loss condition that is characterized by acute onset of non-scarring hair loss in usually sharply defined areas ranging from small patches to extensive or less frequently diffuse involvement. Depending on its acuity and extent, hair loss is an important cause of anxiety and disability. The current understanding is that the condition represents an organ-specific autoimmune disease of the hair follicle with a genetic background. Genome-wide association studies provide evidence for the involvement of both innate and acquired immunity in the pathogenesis, and mechanistic studies in mouse models of alopecia areata have specifically implicated an IFN-γ-driven immune response, including IFNγ, IFNγ-induced chemokines and cytotoxic CD8 T cells as the main drivers of disease pathogenesis. A meta-analysis of published trials on treatment of alopecia areata states that only few treatments have been well evaluated in randomized trials. Nevertheless, depending on patient age, affected surface area and disease duration, an empiric treatment algorithm can be designed with corticosteroids and topical immunotherapy remaining the mainstay of therapy. The obviously limited success of evidence-based therapies points to a more important complexity of hair loss. At the same time, the complexity of pathogenesis offers opportunities for the development of novel targeted therapies. New treatment opportunities based on the results of genome-wide association studies that implicate T cell and natural killer cell activation pathways are paving the way to new approaches in future clinical trials. Currently, there are ongoing studies with the CTLA4-Ig fusion protein abatacept, anti-IL15Rβ monoclonal antibodies and the Janus kinase inhibitors tofacitinib, ruxolitinib and baricitinib. Ultimately, the options available for adapting to the disease rather than treating it in an effort to cure may also be taken into consideration in selected cases of long-standing or recurrent small spot disease.

Entities:  

Keywords:  Alopecia areata; Autoimmune pathogenesis; Corticosteroids; New treatment opportunities; Topical immunotherapy

Mesh:

Substances:

Year:  2018        PMID: 28717940     DOI: 10.1007/s12016-017-8620-9

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  205 in total

1.  Treatment of alopecia areata by anthralin-induced dermatitis.

Authors:  C Schmoeckel; I Weissmann; G Plewig; O Braun-Falco
Journal:  Arch Dermatol       Date:  1979-10

2.  Alopecia Areata et Totalis Cured by Pregnancy, and Relapsing with the Re-establishment of the Menses.

Authors:  G N Meachen; F L Provis
Journal:  Proc R Soc Med       Date:  1912

3.  Alopecia areata but not androgenetic alopecia is characterized by a restricted and oligoclonal T-cell receptor-repertoire among infiltrating lymphocytes.

Authors:  D Dressel; C H Brütt; B Manfras; T M Zollner; A Wunderlich; B O Böhm; W H Boehncke
Journal:  J Cutan Pathol       Date:  1997-03       Impact factor: 1.587

Review 4.  Heritable factors distinguish two types of alopecia areata.

Authors:  V H Price; B W Colombe
Journal:  Dermatol Clin       Date:  1996-10       Impact factor: 3.478

5.  The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata.

Authors:  C Cotellessa; K Peris; E Caracciolo; C Mordenti; S Chimenti
Journal:  J Am Acad Dermatol       Date:  2001-01       Impact factor: 11.527

Review 6.  The role of hair follicle immune privilege collapse in alopecia areata: status and perspectives.

Authors:  Ralf Paus; Marta Bertolini
Journal:  J Investig Dermatol Symp Proc       Date:  2013-12

7.  Estimated serum vitamin D status, vitamin D intake, and risk of incident alopecia areata among US women.

Authors:  Jordan M Thompson; Tricia Li; Min Kyung Park; Abrar A Qureshi; Eunyoung Cho
Journal:  Arch Dermatol Res       Date:  2016-09-23       Impact factor: 3.017

Review 8.  Statins: novel additions to the dermatologic arsenal?

Authors:  M R Namazi
Journal:  Exp Dermatol       Date:  2004-06       Impact factor: 3.960

9.  Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients.

Authors:  A Friedli; M P Labarthe; E Engelhardt; R Feldmann; D Salomon; J H Saurat
Journal:  J Am Acad Dermatol       Date:  1998-10       Impact factor: 11.527

10.  Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata.

Authors:  E A Olsen; S C Carson; E A Turney
Journal:  Arch Dermatol       Date:  1992-11
View more
  24 in total

Review 1.  Bitemporal Scalp Hair Loss: Differential Diagnosis of Nonscarring and Scarring Conditions.

Authors:  Brianna De Souza; Andrea Tovar-Garza; Laura N Uwakwe; Amy McMichael
Journal:  J Clin Aesthet Dermatol       Date:  2021-02-01

2.  Alopecia Areata in Twins With Autoimmune Thyroiditis: Personal Observations.

Authors:  Giusy Schipani; Stefano Dastoli; Elisabetta Scali; Luigi Bennardo; Martina Silvestri; Steven Paul Nisticò
Journal:  Dermatol Pract Concept       Date:  2019-07-31

3.  Role of adiponectin and leptin in patients with alopecia areata with scalp hair loss.

Authors:  Gamze Serarslan; Oğuzhan Özcan; Ebru Okyay; Bahar Ünlü; Mehmet Karadağ
Journal:  Ir J Med Sci       Date:  2020-10-20       Impact factor: 1.568

4.  Chi-miR-370-3p regulates hair follicle morphogenesis of Inner Mongolian cashmere goats.

Authors:  Erhan Hai; Wenjing Han; Zhihong Wu; Rong Ma; Fangzheng Shang; Min Wang; Lili Liang; Youjun Rong; Jianfeng Pan; Zhiying Wang; Ruijun Wang; Rui Su; Yanhong Zhao; Zhihong Liu; Zhixin Wang; Jinquan Li; Yanjun Zhang
Journal:  G3 (Bethesda)       Date:  2021-05-07       Impact factor: 3.154

5.  Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review.

Authors:  Atrin Toussi; Virginia R Barton; Stephanie T Le; Oma N Agbai; Maija Kiuru
Journal:  J Am Acad Dermatol       Date:  2020-06-17       Impact factor: 15.487

6.  CTLA4 +49AG (rs231775) and CT60 (rs3087243) gene variants are not associated with alopecia areata in a Mexican population from Monterrey Mexico.

Authors:  Mauricio Andrés Salinas-Santander; Cristina Susana Cantu-Salinas; Jorge Ocampo-Candiani; Victor de Jesus Suarez-Valencia; Jennifer Guadalupe Ramirez-Guerrero; Celia Nohemi Sanchez-Dominguez
Journal:  An Bras Dermatol       Date:  2020-03-20       Impact factor: 1.896

7.  Exploring the combination and modular characteristics of herbs for alopecia treatment in traditional Chinese medicine: an association rule mining and network analysis study.

Authors:  Jungtae Leem; Wonmo Jung; Yohwan Kim; Bonghyun Kim; Kyuseok Kim
Journal:  BMC Complement Altern Med       Date:  2018-07-04       Impact factor: 3.659

Review 8.  Autoreactive T-Lymphocytes in Inflammatory Skin Diseases.

Authors:  Wolf-Henning Boehncke; Nicolo Costantino Brembilla
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

9.  Reversal of alopecia areata, osteoporosis follow treatment with activation of Tgr5 in mice.

Authors:  Xiaohui Zhou; Zhiqiang Guan; Xiao Jin; Jianbin Zhao; Guisheng Chen; Jicun Ding; Yile Ren; Xiaoxiang Zhai; Qiyun Zhou; Zhiyuan Guan
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

10.  Increased Serum Levels of IFN-γ, IL-1β, and IL-6 in Patients with Alopecia Areata and Nonsegmental Vitiligo.

Authors:  Katarzyna Tomaszewska; Magdalena Kozłowska; Andrzej Kaszuba; Aleksandra Lesiak; Joanna Narbutt; Anna Zalewska-Janowska
Journal:  Oxid Med Cell Longev       Date:  2020-08-03       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.